ARRY stock forecast
Our latest prediction for Array BioPharma, Inc.'s stock price was made on the Feb. 7, 2019 when the stock price was at 21.56$.
In the short term (2weeks), ARRY's stock price should outperform the market by 0.52%. During that period the price should oscillate between -7.29% and +8.24%.
In the medium term (3months), ARRY's stock price should outperform the market by 4.18%. During that period the price should oscillate between -16.42% and +24.24%.Get email alerts
Create a solid portfolio with ARRY
About Array BioPharma, Inc.
Array BioPharma, Inc. engages in the research, development, and commercialization of targeted small molecule drugs for the treatment of cancer and other high-burden diseases. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO.
At the moment the company generates 241M USD in revenues.
On its last earning announcement, the company reported a loss of -0.53$ per share.
The book value per share is 1.03$
Three months stock forecastFeb. 7, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|